The purpose of this study is to evaluate the efficacy and safety of zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP for the treatment of the GCB subtype of DLBCL.

The purpose of the study is to find out is AUTX-007 an investigational drug, can help treat or cure cancer.

In this study, we want to look at how the drug tirzepatide works in patients with endometrial cancer compared to the standard of care treatment. We will be looking at its effect on the progression of the tumor.

Testing Radiation Therapy with or without Cisplatin for Head and Neck Cancer

Are you a young adult who drinks and uses social media? We are holding in-person workshops in downtown Chapel Hill to gather feedback from young adults who drink and use social media. Compensation provided.

In this study, we want to see if a new drug called LBS-007 can help treat or cure leukemia. We want to find out if it is safe and if it works well for people with this disease.

The purpose of this study is to explore the safety and efficacy of a study drug called Telisotuzumab adizutecan (ABBV-400) in combination with existing therapies in Metastatic Colorectal Cancer (mCRC) patients.

The purpose of this research is to test the safety of NXC-201 (a CAR-T cell targeting the BCMA protein) at different doses in participants with relapsed/refractory AL amyloidosis, and to confirm the best dose for further testing. In addition, the study will evaluate the effectiveness of NXC-201 in treating relapsed/refractory AL amyloidosis

The main purpose of the study is to determine whether the experimental study drug, AI-081, is safe and well tolerated, and whether it is effective in treating advanced cancer that cannot be removed by surgery or has spread to a different part of the body (metastasis).

The purpose of this study is to determine whether a new investigational combination of drugs, that contains belantamab mafodotin with belantamab, will be as effective, and more tolerable, compared to belantamab mafodotin alone in participants with multiple myeloma that has become active again after at least three prior lines of treatment.